Technology insight: Measuring prolactin in clinical samples

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 3, 2007, Pages 279-289

  Smith, Thomas P ^a,b   Kavanagh, Lucille ^c   Healy, Marie Louise ^c   McKenna, T Joseph ^b,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Hyperprolactinemia; Interference; Macroprolactin; Prolactin

Indexed keywords

BROMOCRIPTINE; PERGOLIDE; PROLACTIN;

ANAMNESIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; GEL FILTRATION CHROMATOGRAPHY; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; IMMUNOASSAY; MACROPROLACTINEMIA; MICROADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; REVIEW;

DIAGNOSTIC ERRORS; DIAGNOSTIC TECHNIQUES, ENDOCRINE; HUMANS; HYPERPROLACTINEMIA; MODELS, BIOLOGICAL; PROLACTIN;

EID: 33847210363     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0447     Document Type: Review

References (62)

1. Jeffcoate SL et al. (1986) Assays for prolactin: guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem 23: 638-651
2. Gibney J et al. (2005) The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 90: 3927-3932
3. Fahie-Wilson MN and Soule SG (1997) Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 34: 252-258
4. Olukoga AO et al. (1999) Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 51: 119-126
5. Leslie H et al. (2001) Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 86: 2743-2746
6. Strachan MW et al. (2003) Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf) 59: 339-346
7. Fraser IS et al. (1989) Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab 69: 585-592
8. Hattori N et al. (1997) Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab 82: 3107-3110
9. Larrea F et al. (1985) Further evidence that big, big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function. Fertil Steril 44: 25-30
10. Foglia G (2001) Prolactinomas and hyperprolactinemic syndromes. In Endocrinology, 329-342 (Eds De Groot LJ and Jameson JL) Philadelphia: WB Saunders
11. Bergh T et al. (2002) Hyperprolactinaemic anovulation. In Oxford Textbook of Endocrinology and Diabetes, 1130-1134 (Eds Wass J and Shalet S) Oxford: Oxford University Press
12. Mah PM et al. (2002) Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 20: 365-374
13. Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5: 55-65
14. Luciano AA et al. (1985) Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 65: 506-510
15. Luciano AA et al. (1984) Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril 41: 719-725
16. Melmed S et al. (2002) Anterior pituitary. In Williams Textbook of Endocrinology, 177-279 (Eds Williams RH et al.) Philadelphia: WB Saunders
17. Thorner MO et al. (1998) The anterior pituitary. In Williams Textbook of Endocrinology, 249-340 (Eds Wilson JD et al.) Philadelphia: WB Saunders
18. Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16: 354-369
19. Hattori N et al. (1992) A normal ovulatory woman with hyperprolactinemia: presence of anti-prolactin autoantibody and the regulation of prolactin secretion. Acta Endocrinol (Copenh) 126: 497-500
20. Leite V et al. (1992) Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 37: 365-372
21. Rosato F et al. (2002) Hyperprolactinemia: from diagnosis to treatment. Minerva Pediatr 54: 547-552
22. Sam S et al. (2005) The pituitary mass: diagnosis and management. Rev Endocr Metab Disord 6: 55-62
23. Smith T et al. (1998) Prevalence of macroprolactinemia in various hyperprolactinemic states [abstract]. Irish J Med Sci 167: 6
24. Klibanski A et al. (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67: 124-130
25. Lewis UJ et al. (2000) Structure and properties of members of the hGH family: a review. Endocr J 47: S1-S8
26. Suliman AM et al. (2003) Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 49: 1504-1509
27. Freeman ME et al. (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80: 1523-1631
28. Bayrak A et al. (2005) Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril 84: 181-185
29. Smith TP et al. (2002) Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 87: 5410-5415
30. Hattori N et al. (2006) Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol 190: 287-293
31. Rogol AD et al. (1974) Prolactin of apparent large molecular size: the major immunoactive prolactin component in plasma of a patient with a pituitary tumor. J Clin Endocrinol Metab 38: 714-717
32. Fahie-Wilson MN et al. (2005) Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 42: 175-192
33. Tritos NA et al. (1998) Asymptomatic 'big' hyperprolactinemia in two men with pituitary adenomas. Eur J Endocrinol 138: 82-85
34. Ellis AR and Fahie-Wilson M (2005) Method recognition of big prolactin in serum and prolactin in amniotic fluid. In UK NEQAS for Peptide Hormones and Related Substances, Annual Review 2005, A1-A4 (Eds Ellis AR et al.) Edinburgh: United Kingdom National External Quality Assessment Service
35. Kavanagh L et al. (2006) Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem 52: 1366-1372
36. Schlechte JA (2002) The macroprolactin problem. J Clin Endocrinol Metab 87: 5408-5409
37. Fahie-Wilson M (2003) In hyperprolactinemia, testing for macroprolactin is essential. Clin Chem 49: 1434-1436
38. Olukoga AO et al. (1999) Three cases of macroprolactinaemia. J R Soc Med 92: 342-344
39. Heaney AP et al. (1999) Misleading hyperprolactinaemia in pregnancy. Lancet 353: 720
40. Guay AT et al. (1996) Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J Clin Endocrinol Metab 81: 2512-2514
41. Cattaneo FA et al. (2001) Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall. Case report. J Neurosurg 95: 334-337
42. Gibney J et al. (2005) Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 62: 633-643
43. Hattori N et al. (1992) Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab 75: 1226-1229
44. Vieira JG et al. (1998) Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin Chem 44: 1758-1759
45. Haller BL et al. (1992) Two automated prolactin immunoassays evaluated with demonstration of a high-dose hook effect in one. Clin Chem 38: 437-438
46. Petakov MS et al. (1998) Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 21: 184-188
47. St-Jean E et al. (1996) High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 44: 305-309
48. Frieze TW et al. (2002) "Hook effect" in prolactinomas: case report and review of literature. Endocr Pract 8: 296-303
49. Schofl C et al. (2002) Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary 5: 261-265
50. Ismail AA (2005) A radical approach is needed to eliminate interference from endogenous antibodies in immunoassays. Clin Chem 51: 25-26
51. Kircka L (2000) Interferences in immunoassay - still a threat. Clin Chem 46: 1037-1038
52. Preissner CM et al. (2005) Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem 51: 208-210
53. Bjerner J et al. (2005) Human heterophilic antibodies display specificity for murine IgG subclasses. Clin Biochem 38: 465-472
54. Bjerner J et al. (2005) The war on heterophilic antibody Interference. Clin Chem 51: 9-11
55. Sapin R and Simon C (2001) False hyperprolactinemia corrected by the use of heterophilic antibody-blocking agent. Clin Chem 47: 2184-2185
56. Kricka LJ et al. (1990) Interference by human anti-mouse antibody in two-site immunoassays. Clin Chem 36: 892-894
57. Madry N et al. (1997) Measures to overcome HAMA interferences in immunoassays. Anticancer Res 17: 2883-2886
58. Nussbaum S et al. (2000) Human anti-mouse antibodies: pitfalls in tumor marker measurement and strategies for enhanced assay robustness; including results with Elecsys CEA. Anticancer Res 20: 5249-5252
59. Webster J et al. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331: 904-909
60. Molitch ME et al. (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60: 698-705
61. Biller BM et al. (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81: 2338-2343
62. Di Somma C et al. (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83: 807-813